Press Enter to search · Esc to close
A Hong Kong cohort suggests the trendy 1-hour glucose test isn't always the smarter pick — especially if young-onset type 2 diabetes runs in your family.
A new Thai cohort study sorts pre-diabetic adults into six clusters with sharply different risks for type 2 diabetes, vascular damage and death — a glimpse of metabolic care that finally treats people as individuals.
A new UK Biobank analysis suggests that how fast you're aging on the inside can amplify the genetic odds of diabetes and heart disease — and measuring both may sharpen the picture.
A 2025 systematic review maps where plant-based eating moves the metabolic needle — and where the evidence still thins out. Here's what a busy 40-year-old should actually take from it.
A multinational cohort sketches who's really starting GLP-1s for diabetes and kidney disease — and a new mouse study hints these drugs may rewire taste itself.
Patients are shuffling between Ozempic, dulaglutide, and tirzepatide. A small case series and a new biosimilar trial offer the first grounded signals on how this class is fragmenting — and what switching really looks like.
Phase III data on IcoSema and fresh SURMOUNT analyses of tirzepatide are rewriting what 'best-in-class' looks like for metabolic and obesity care.
A three-year cohort of type 2 diabetics tracked who silently progressed to liver fibrosis — and which routine lab markers offered the earliest warning.
A new meta-analysis confirms GLP-1 drugs protect the heart and kidneys. Real-world data suggests pairing them with SGLT2 inhibitors may compound the benefit — with caveats worth understanding.
A real-world analysis tied to the dulaglutide shortage put concrete numbers on what happens to blood sugar in the three months after stopping. The picture is sobering — and worth bringing to your doctor.